Alimera Sciences' CEO Dan Myers to Present During Ophthalmology Innovation Summit at American Academy of Ophthalmology 2017
November 07 2017 - 7:30AM
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the
commercialization and development of prescription ophthalmic
pharmaceuticals, today announced that Dan Myers, Chief Executive
Officer of Alimera, will present at the Ophthalmology Innovation
Summit (OIS) to be held Thursday, November 9, 2017 in conjunction
with the 2017 American Academy of Ophthalmology (AAO) in New
Orleans. Mr. Myers will be speaking as part of the Public
Device and BioPharma Company Showcase scheduled for 3:35-4:45 p.m.
OIS unites industry, entrepreneurial and clinical leaders to
collaborate on the development and commercialization of innovative
drugs and devices to address unmet clinical needs. At OIS@AAO, Mr.
Myers will present real-world data from the USER (U.S.
Retrospective Chart Review in Patients Receiving ILUVIEN®) Study,
as well as provide an update on Alimera's progress toward securing
for ILUVIEN an indication for posterior uveitis in Europe.
"We welcome the opportunity to discuss our accomplishments and
our vision with other leaders in the ophthalmic industry at OIS,"
said Mr. Myers. "OIS@AAO is always a great day to highlight ILUVIEN
and Alimera, especially now that we can share how the continuous
microdosing of ILUVIEN provides a unique opportunity to treat DME
consistently everyday by reducing the treatment frequency for
physicians and patients."
The slides used in Mr. Myers’ presentation will be posted on the
Alimera website, www.alimerasciences.com, prior to the meeting.
About ILUVIEN
www.ILUVIEN.com.
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is
a sustained release intravitreal implant approved in the U.S. to
treat diabetic macular edema (DME) in patients who have been
previously treated with a course of corticosteroids and did not
have a clinically significant rise in intraocular pressure. Each
ILUVIEN implant is designed to release submicrogram levels of
fluocinolone acetonide, a corticosteroid, for 36 months to treat
DME consistently every day.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic
retinopathy, is a disease affecting the macula, the part of the
retina responsible for central vision. When the blood vessel
leakage associated with diabetic retinopathy results in swelling of
the macula, the condition is called DME. The onset of DME is
painless and may go unreported by the patient until it manifests
with the blurring of central vision or acute vision loss. The
severity of this blurring may range from mild to profound loss of
vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy
found that over a 10-year period approximately 19% of people with
diabetes included in the study were diagnosed with DME. All people
with type 1 or type 2 diabetes are at risk of developing DME.
About Alimera Sciences, Inc.
www.alimerasciences.com
Alimera, founded in June 2003, is a pharmaceutical company
that specializes in the commercialization, research, and
development of prescription ophthalmic pharmaceuticals. Alimera is
presently focused on diseases affecting the back of the eye, or
retina, because these diseases are not well treated with current
therapies and will affect millions of people in our aging
populations. Alimera’s commitment to retina specialists and their
patients is manifest in Alimera’s product and development portfolio
designed to treat early- and late-stage diseases. For more
information, please visit www.alimerasciences.com.
For press inquiries:Katie Brazelfor Alimera
Sciences 404-317-8361kbrazel@bellsouth.net
For investor inquiries:CG Capitalfor Alimera
Sciences877-889-1972investorrelations@cg.capital
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2023 to Apr 2024